KRAS and colorectal carcinoma: As the sequel of our previous published work, in this study, we specifically targeted CRC cells harboring the KRAS mutation and the results showed that KRAS-mutant CRC cells are adequately resistant to cetuximab (anti-EGFR monoclonal antibodies).